AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20008828 — intervention group
Group type: EXPERIMENTAL
Intervention: supplemented very low-protein diet (sVLPD)
Number of subjects: 57
Study 20008828 — intervention group
Group type: COMPARATOR
Intervention: dialysis
Number of subjects: 57
Study 18069904 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-828L 5 g/d for 56 days
Number of subjects: 84
Study 18069904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 15469666 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (150 mg)
Number of subjects: 15
Study 15469666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14551544 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic PCL reconstruction using looped autogenous hamstring tendons and an EndoButton.
Number of subjects: 51
Study 14551544 — intervention group
Group type: COMPARATOR
Intervention: 2-incision PCL reconstruction using autogenous hamstring tendons.
Number of subjects: 51
Study 14551544 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic PCL reconstruction
Number of subjects: 51
Study 10648333 — intervention group
Group type: EXPERIMENTAL
Intervention: MST 20 mg 12 hourly
Number of subjects: 0
Study 10648333 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate 10 mg IM 6 hourly
Number of subjects: 0
Study 9025796 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic carbohydrate drink
Number of subjects: 20
Study 9025796 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (flavored water)
Number of subjects: 20
Study 1496093 — intervention group
Group type: EXPERIMENTAL
Intervention: High combat with high social support
Number of subjects: 80
Study 1496093 — intervention group
Group type: EXPERIMENTAL
Intervention: High combat with low social support
Number of subjects: 80
Study 1496093 — intervention group
Group type: EXPERIMENTAL
Intervention: Low combat with high social support
Number of subjects: 80
Study 1496093 — intervention group
Group type: EXPERIMENTAL
Intervention: Low combat with low social support
Number of subjects: 80
Study 6149758 — intervention group
Group type: EXPERIMENTAL
Intervention: +cyanidanol-3 (2 g daily, 500 mg qds)
Number of subjects: 0
Study 6149758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3780692 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal blockade with 0.5% bupivacaine (3 ml)
Number of subjects: 60
Study 3780692 — intervention group
Group type: COMPARATOR
Intervention: Epidural blockade with 0.5% bupivacaine (19 ml)
Number of subjects: 60
Study 30045422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Melissa officinalis (MO) 3 g/d
Number of subjects: 80
Study 30045422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28679551 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load diet
Number of subjects: 0
Study 28679551 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic load diet
Number of subjects: 0
Study 28679551 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet
Number of subjects: 0
Study 28679551 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 28679551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat and low-carbohydrate diet
Number of subjects: 0
Study 28679551 — intervention group
Group type: COMPARATOR
Intervention: Low-fat and high-carbohydrate diet
Number of subjects: 0
Study 25701171 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab plus pemetrexed and cisplatin
Number of subjects: 633
Study 25701171 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed and cisplatin alone
Number of subjects: 633
Study 23069274 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Finnish‐Swedish bilinguals
Number of subjects: 2
Study 23069274 — intervention group
Group type: COMPARATOR
Intervention: Monolingual native speakers of Finnish
Number of subjects: 2
Study 20531162 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) intervention consisting of eight 90‐min sessions with 30 mins of each session devoted to PT, focusing on truncal and limb isodynamic strengthening and education.
Number of subjects: 103
Study 20531162 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 103
Study 20531162 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) intervention
Number of subjects: 103
Study 17713476 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (single-dose escalation study)
Number of subjects: 0
Study 17713476 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (multiple-dose escalation study)
Number of subjects: 0
Study 17713476 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (single-dose female study)
Number of subjects: 0
Study 17713476 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (general findings)
Number of subjects: 0
Study 17149454 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (1 hour instructional session, followed by 4 weeks of daily home practice)
Number of subjects: 25
Study 17149454 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (combined pre- and postintervention data)
Number of subjects: 25
Study 17149454 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (subjective feedback)
Number of subjects: 25
Study 17149454 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (before receiving yoga intervention)
Number of subjects: 25
Study 12511185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitive (IS) patients
Number of subjects: 61
Study 12511185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant (IR) patients
Number of subjects: 61
Study 12511185 — intervention group
Group type: COMPARATOR
Intervention: Both groups (IS and IR)
Number of subjects: 61
Study 9828796 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fast FLAIR sequence
Number of subjects: 10
Study 9828796 — intervention group
Group type: COMPARATOR
Intervention: CSE (conventional spin echo)
Number of subjects: 10
Study 7859960 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed group (received flumazenil before colonoscope withdrawal)
Number of subjects: 81
Study 7859960 — intervention group
Group type: COMPARATOR
Intervention: Not-reversed group (did not receive flumazenil before colonoscope withdrawal)
Number of subjects: 81
Study 7859960 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior intravenous sedation (second phase)
Number of subjects: 81
Study 2680158 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg once daily)
Number of subjects: 406
Study 2680158 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg three times daily)
Number of subjects: 406
Study 2680158 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (325 mg and 75 mg, respectively, three times daily)
Number of subjects: 406
Study 2680158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (267 mg three times daily)
Number of subjects: 406
Study 2680158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 406
Study 2680158 — intervention group
Group type: EXPERIMENTAL
Intervention: All aspirin groups combined
Number of subjects: 406
Study 2680158 — intervention group
Group type: EXPERIMENTAL
Intervention: All aspirin groups for grafts to vessels ≤ 2.0 mm
Number of subjects: 406
Study 2680158 — intervention group
Group type: EXPERIMENTAL
Intervention: All aspirin groups for grafts to vessels > 2.0 mm
Number of subjects: 406
Study 827773 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 13
Study 827773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30282861 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g butter (B10)
Number of subjects: 0
Study 30282861 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g butter (B20)
Number of subjects: 0
Study 30282861 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g butter (B40)
Number of subjects: 0
Study 30282861 — intervention group
Group type: COMPARATOR
Intervention: 0 g butter (control)
Number of subjects: 0
Study 26440437 — intervention group
Group type: COMPARATOR
Intervention: IV tramadol (2 mg/kg, 3 mL)
Number of subjects: 40
Study 26440437 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration with tramadol (2 mg/kg, 3 mL)
Number of subjects: 40
Study 25241302 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux microcatheter (ARM)
Number of subjects: 30
Study 25241302 — intervention group
Group type: COMPARATOR
Intervention: Coil embolization
Number of subjects: 30
Study 25241302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 22388325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-late systolic MR
Number of subjects: 201
Study 22388325 — intervention group
Group type: COMPARATOR
Intervention: Holosystolic MR
Number of subjects: 201
Study 20848729 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacologic and pharmacologic options for ovulation induction
Number of subjects: 0
Study 20848729 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study 18544622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 IU daily
Number of subjects: 48
Study 18544622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,500 IU once weekly
Number of subjects: 48
Study 18544622 — intervention group
Group type: EXPERIMENTAL
Intervention: 45,000 IU once every 28 days
Number of subjects: 48
Study 15872124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg plus metoclopramide 10 mg iv
Number of subjects: 90
Study 15872124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg iv
Number of subjects: 90
Study 15872124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 90
Study 15385009 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous placement (30 seconds after loss of lid reflex)
Number of subjects: 0
Study 15385009 — intervention group
Group type: COMPARATOR
Intervention: Late intravenous placement (120 seconds after loss of lid reflex)
Number of subjects: 0
Study 10073791 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin and etofibrate combination
Number of subjects: 0
Study 10073791 — intervention group
Group type: COMPARATOR
Intervention: Niacin alone
Number of subjects: 0
Study 7739926 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (200 U/kg i.v. three times a week during 4 weeks)
Number of subjects: 13
Study 7739926 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control group)
Number of subjects: 13
Study 2197059 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic carotid endarterectomy for critical lesions
Number of subjects: 0
Study 2197059 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 2197059 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 0
Study 394281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltarol) 25 mg t.d.s. for 2 weeks
Number of subjects: 67
Study 394281 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg t.d.s. for 2 weeks
Number of subjects: 67
Study 30041540 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative feeding (EPF) at 4 hours postoperatively
Number of subjects: 140
Study 30041540 — intervention group
Group type: COMPARATOR
Intervention: Late postoperative feeding (LPF) at 8 hours or more postoperatively
Number of subjects: 140
Study 30107043 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg, twice daily for 52 weeks
Number of subjects: 102
Study 30107043 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 52 weeks
Number of subjects: 102
Study 27399104 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing CCTA (group B)
Number of subjects: 80
Study 27399104 — intervention group
Group type: COMPARATOR
Intervention: Breath-holding CCTA (group A)
Number of subjects: 80
Study 25231565 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bioresonance therapy
Number of subjects: 190
Study 25231565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 22614031 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB-DOX)
Number of subjects: 173
Study 19874636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-almond diet (20% isoenergetic replacement of control diet with almonds)
Number of subjects: 25
Study 19874636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-almond diet (10% isoenergetic replacement of control diet with almonds)
Number of subjects: 25
Study 19874636 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no nuts, < 30% energy from fat)
Number of subjects: 25
Study 17324006 — intervention group
Group type: EXPERIMENTAL
Intervention: orBec® (beclometasone)
Number of subjects: 129
Study 17324006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 16203880 — intervention group
Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty
Number of subjects: 42
Study 16203880 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 42
Study 11990662 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous biventricular defibrillation using a left venous access defibrillation electrode (LVA lead)
Number of subjects: 24
Study 11990662 — intervention group
Group type: COMPARATOR
Intervention: Standard right ventricular defibrillation system
Number of subjects: 24
Study 11990662 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous biventricular defibrillation
Number of subjects: 24
Study 10380428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal drugs
Number of subjects: 0
Study 10380428 — intervention group
Group type: COMPARATOR
Intervention: C. albicans antigen
Number of subjects: 0
Study 8671157 — intervention group
Group type: EXPERIMENTAL
Intervention: Follegon
Number of subjects: 16
Study 8671157 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrodin
Number of subjects: 16
Study 1816280 — intervention group
Group type: EXPERIMENTAL
Intervention: prazepam + ethanol
Number of subjects: 12
Study 1816280 — intervention group
Group type: COMPARATOR
Intervention: prazepam alone
Number of subjects: 12
Study 1816280 — intervention group
Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 12
Study 1816280 — intervention group
Group type: COMPARATOR
Intervention: placebo + ethanol
Number of subjects: 12
Study 6751374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta-carotene
Number of subjects: 0
Study 6751374 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 6751374 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzimidazole sunscreen cream
Number of subjects: 0
Study 6751374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 0
Study 31481683 — intervention group
Group type: EXPERIMENTAL
Intervention: Seltorexant (JNJ-42847922/MIN-202)
Number of subjects: 47
Study 31481683 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 47
Study 28126898 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (6.75 mg)
Number of subjects: 830
Study 28126898 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (40 μg)
Number of subjects: 830
Study 26820158 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E, C, A, and N-acetylcysteine daily (treatment group)
Number of subjects: 29
Study 26820158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 29
Study 26820158 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 29
Study 24877167 — intervention group
Group type: EXPERIMENTAL
Intervention: MuGard
Number of subjects: 120
Study 24877167 — intervention group
Group type: COMPARATOR
Intervention: Sham control rinse (SC)
Number of subjects: 120
Study 20624657 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 12 mg
Number of subjects: 469
Study 20624657 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg
Number of subjects: 469
Study 20624657 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3 mg
Number of subjects: 469
Study 20624657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 20334503 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative GOSE rating system coupled with central quality control (Group 1)
Number of subjects: 45
Study 20334503 — intervention group
Group type: COMPARATOR
Intervention: Alternative GOSE rating system alone (Group 2)
Number of subjects: 45
Study 20334503 — intervention group
Group type: COMPARATOR
Intervention: Conventional structured interviews (Group 3)
Number of subjects: 45
Study 17265397 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered sharps injury prevention device (ESIPD) - intravenous (IV) catheter stylet with a safety-engineered feature (retractable protection shield)
Number of subjects: 0
Study 17265397 — intervention group
Group type: COMPARATOR
Intervention: Suture needles (no protective devices present)
Number of subjects: 0
Study 16344034 — intervention group
Group type: EXPERIMENTAL
Intervention: BROM device for measuring side bending
Number of subjects: 91
Study 16344034 — intervention group
Group type: EXPERIMENTAL
Intervention: BROM device for measuring lumbar forward flexion and pelvic inclination
Number of subjects: 91
Study 16344034 — intervention group
Group type: EXPERIMENTAL
Intervention: BROM device for measuring lumbar extension and rotation
Number of subjects: 91
Study 16344034 — intervention group
Group type: EXPERIMENTAL
Intervention: BROM device for measuring all lumbar motions and pelvic inclination
Number of subjects: 91
Study 16344034 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation consistency
Number of subjects: 91
Study 12413985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone, 2.5 mg/d for 4 months
Number of subjects: 30
Study 12413985 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 30
Study 10220653 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-Temp luting agent
Number of subjects: 10
Study 10220653 — intervention group
Group type: COMPARATOR
Intervention: Temp Bond luting agent
Number of subjects: 10
Study 10220653 — intervention group
Group type: COMPARATOR
Intervention: Provilink luting agent
Number of subjects: 10
Study 8101011 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 2
Study 8101011 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2
Study 3826569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Stimulator Technique (NST)
Number of subjects: 60
Study 3826569 — intervention group
Group type: COMPARATOR
Intervention: Perivascular Catheter Technique (PVT)
Number of subjects: 60
Study 3826569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study 30012116 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month evidence-based behaviour change program via the TRavelVU Plus app
Number of subjects: 250
Study 30012116 — intervention group
Group type: COMPARATOR
Intervention: Monitoring of active transport via the TRavelVU app
Number of subjects: 250
Study 27015966 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic and Smoking Reduction Treatment (PSRT) + d-cycloserine (DCS)
Number of subjects: 0
Study 27015966 — intervention group
Group type: COMPARATOR
Intervention: Panic and Smoking Reduction Treatment (PSRT) + placebo
Number of subjects: 0
Study 24496783 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 5‐7 cm H2O during the first 6 h after surgery
Number of subjects: 110
Study 24496783 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask supplemental oxygen
Number of subjects: 110
Study 22622911 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic and steroids
Number of subjects: 16
Study 22622911 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic only
Number of subjects: 16
Study 22622911 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections (unspecified)
Number of subjects: 16
Study 19826409 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT delivered by mail
Number of subjects: 26255
Study 19826409 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT delivered by GP/screening facility
Number of subjects: 26255
Study 19826409 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐only sigmoidoscopy
Number of subjects: 26255
Study 19826409 — intervention group
Group type: EXPERIMENTAL
Intervention: FS followed by FOBT for screenees with negative FS
Number of subjects: 26255
Study 19826409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's choice between FS and FOBT
Number of subjects: 26255
Study 18050178 — intervention group
Group type: COMPARATOR
Intervention: Intervention group I (information on arthritis self-management through GPs)
Number of subjects: 1021
Study 18050178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group II (information on arthritis self-management + additional case management via telephone by practice nurse)
Number of subjects: 1021
Study 18050178 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1021
Study 16075363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oral clodronate (1.6 g/day) for 3 years
Number of subjects: 299
Study 16075363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 299
Study 12365910 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular translocation with 360° peripheral retinectomy and silicone oil tamponade
Number of subjects: 15
Study 10189133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 10 mg twice daily
Number of subjects: 135
Study 10189133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus octreotide 150 microg (subcutaneously thrice daily)
Number of subjects: 135
Study 10189133 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 135
Study 10189133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus octreotide
Number of subjects: 135
Study 10189133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus octreotide
Number of subjects: 135
Study 8944997 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filters
Number of subjects: 50